Codexis (CDXS) CEO Alison Moore Sells $8.6K of Stock

Alison Moore, the President and CEO of Codexis, Inc. (NasdaqGS: CDXS), sold 6,335 shares on October 12, 2026. The shares were sold at an average price of $1.36, bringing in about $8,619.40.

Inside Alison Moore's Trade

Moore's recent sale adds to the pattern of insider trading at Codexis. This is not her first transaction; multiple insiders bought shares on June 17, 2026, when they acquired 66,350 shares each. However, Moore's sale comes at a time when the stock is trading below its 50-day and 200-day moving averages, which may raise questions among investors.

Other Institutional Activity in Codexis

Several institutional investors have also adjusted their stakes in Codexis recently. Blackrock Inc. grew its holdings by 255,838 shares, ending with 7,284,352 shares worth about $9,032,596. Millennium Management LLC increased its position by 1,550,912 shares, totaling 5,549,139 shares valued at approximately $6,880,932. Meanwhile, Aberdeen Group plc reduced its stake by 1,910,587 shares to 6,769,954 shares valued at around $8,394,743.

Codexis, Inc. Stock Down 8.5%

As of October 16, 2026, Codexis shares were recently traded around $1.25, which is about 14.5% below its 50-day moving average of $1.46 and 32.1% below its 200-day average of $1.84. The stock is also down 58.1% from its 52-week high of $2.98, although it remains 30.2% above its 52-week low of $0.96.

Recent Earnings

In its most recent financials, Codexis reported trailing twelve-month revenue of $77,679,000 with an EPS of -$0.33. The company has faced challenges, reflected in a year-over-year revenue growth decline of 2.7% and a net margin of -39.6%. The next earnings report is scheduled for November 5, 2026.

Insider Buying and Selling at Codexis, Inc.

In addition to Moore's sale, several insiders have been active recently. On June 17, 2026, De Vre Raymond, Cynthia Collins, Dilly Stephen George, and Esther Martinborough each bought 66,350 shares at a price of $0.00, indicating their confidence in the company's future despite the recent downturn in share price.

Analysts Set New Price Targets

On August 17, 2026, Piper Sandler maintained an Overweight rating on Codexis with a price target of $8.00, down from a previous target of $9.00. The analysts' consensus price target for Codexis is $6.14, based on seven analyst opinions, suggesting potential for recovery from current levels.

About Codexis, Inc.

Codexis, Inc. develops technology solutions for manufacturing therapeutics, using its proprietary CodeEvolver technology. The company focuses on discovering and commercializing novel enzymes to enhance the production of RNAi therapeutics through its ECO Synthesis platform. This strategic focus positions Codexis within the growing biotechnology industry, although it faces revenue and profitability challenges.

Bottom Line

Investors will be watching Codexis closely as it approaches its next earnings date on November 5, 2026. Moore's recent sale and the mixed activity from other insiders provide insight into the company's current sentiment, while analysts continue to see potential upside despite recent struggles.